Cellectar Biosciences, Inc. (NASDAQ: CLRB) is developing phospholipid drug conjugates (PDCs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells, according to the company’s website (see here: www.CellectarBiosciences.com). SNNLive spoke with Jim Caruso, President & CEO of Cellectar Biosciences, Inc. at the Marcum MicroCap Conference 2016 in New York City, NY.
In this video interview, Mr. Caruso and our host discuss the following topics:
- Overview of Cellectar Biosciences, Inc.
- Clinical Development
- Intellectual property
- Comments on recent news
- Target indications
- Where the science comes from
- Mr. Caruso’s background
For more information about Cellectar Biosciences, Inc., please visit: www.CellectarBiosciences.com
The interview may contain forward-looking statements about Cellectar Biosciences, Inc. See Cellectar Biosciences periodic filings with the Securities and Exchange Commission for more complete information.
© 2017 Stock News Now
Supported by Superior Web Solutions